awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38839151-2C7CB007-0F10-415D-BDD4-6B58AD64FE07
Q38839151-2C7CB007-0F10-415D-BDD4-6B58AD64FE07
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38839151-2C7CB007-0F10-415D-BDD4-6B58AD64FE07
A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
P2860
Q38839151-2C7CB007-0F10-415D-BDD4-6B58AD64FE07
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38839151-2C7CB007-0F10-415D-BDD4-6B58AD64FE07
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c3d8e49c7be0c174b364b9c562465ab8ade400b8
P2860
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.